Detalles de la búsqueda
1.
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Breast Cancer Res Treat
; 203(1): 163-172, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37773555
2.
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Future Oncol
; : 1-14, 2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592002
3.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308971
4.
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Int J Mol Sci
; 24(14)2023 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37511178
5.
Trajectories of alcohol consumption during life and the risk of developing breast cancer.
Br J Cancer
; 125(8): 1168-1176, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34483338
6.
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain.
Oncologist
; 25(9): e1339-e1345, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652782
7.
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Breast J
; 25(2): 219-225, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30734437
8.
Experience with eribulin in patients with breast cancer and cutaneous metastases: case studies.
Future Oncol
; 14(7s): 37-44, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611759
9.
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
Breast Cancer Res Treat
; 162(1): 181-189, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28040858
10.
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
BMC Cancer
; 17(1): 210, 2017 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28330468
11.
Physical activity and breast cancer risk by pathological subtype.
Gynecol Oncol
; 144(3): 577-585, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28057355
12.
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.
Oncologist
; 20(2): 111-2, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25601966
13.
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Clin Transl Oncol
; 26(7): 1539-1548, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38336982
14.
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.
Eur J Cancer
; 196: 113420, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38000218
15.
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Clin Cancer Res
; 30(10): 2160-2169, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38466643
16.
Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
Oncologist
; 18(8): 917-23, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23873719
17.
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022).
Clin Transl Oncol
; 25(9): 2665-2678, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37148499
18.
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Clin Cancer Res
; 29(2): 389-400, 2023 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346687
19.
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
JAMA Oncol
; 9(6): 841-846, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37103916
20.
Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study.
Cancers (Basel)
; 15(18)2023 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37760421